Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
52
CATX Quote, Financials, Valuation and Earnings
Last price:
$2.8600
Seasonality move
:
14.67%
Day range:
$2.6500 - $2.9550
52-week range:
$1.6000 - $5.3881
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
192.56x
P/B ratio:
0.87x
Volume:
1.9M
Avg. volume:
1.3M
1-year change:
-19.55%
Market cap:
$211.1M
Revenue:
$1.5M
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingPerspective Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.3077, Perspective Therapeutics, Inc. has an estimated upside of 333.37% from its current price of $2.8400.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.0000 representing -40.85% downside risk from its current price of $2.8400.
Fair Value
-
According to the consensus of 13 analysts, Perspective Therapeutics, Inc. has 333.37% upside to fair value with a price target of $12.3077 per share.
CATX vs. S&P 500
-
Over the past 5 trading days, Perspective Therapeutics, Inc. has overperformed the S&P 500 by 0.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Perspective Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Perspective Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Perspective Therapeutics, Inc. reported revenues of $209K.
Earnings Growth
-
Perspective Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Perspective Therapeutics, Inc. reported earnings per share of -$0.35.
Enterprise value:
40.3M
EV / Invested capital:
--
Price / LTM sales:
192.56x
EV / EBIT:
--
EV / Revenue:
37.48x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-0.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.9M
Return On Assets:
-31.7%
Net Income Margin (TTM):
-9884.19%
Return On Equity:
-37.63%
Return On Invested Capital:
-37.13%
Operating Margin:
-13330.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.6M | $1.5M | $1.1M | $369K | $209K | |
| Gross Profit | $1.4M | -$310K | -$1.9M | -$300K | -$566K | |
| Operating Income | -$31.4M | -$55.7M | -$94.6M | -$18.6M | -$27.9M | |
| EBITDA | -$30.6M | -$53.8M | -$91.7M | -$18M | -$27.1M | |
| Diluted EPS | -$0.93 | -$1.01 | -$1.46 | -$0.21 | -$0.35 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65M | $57.5M | $21.7M | $270.2M | $178.5M | |
| Total Assets | $68.7M | $62.5M | $110.5M | $391.2M | $294.8M | |
| Current Liabilities | $1.8M | $4M | $8.1M | $28.1M | $20.6M | |
| Total Liabilities | $3M | $4.8M | $11.7M | $62.7M | $52.6M | |
| Total Equity | $65.8M | $57.7M | $98.8M | $328.5M | $242.2M | |
| Total Debt | $459K | -- | $3M | $3.4M | $2.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.8M | -- | -$84.4M | $3.4M | -$16.3M | |
| Cash From Investing | $24.3M | -- | -$125.9M | -$29.7M | $14M | |
| Cash From Financing | $433K | -- | $10.7M | $628K | $213K | |
| Free Cash Flow | -$31.9M | -- | -$106.9M | -$26.4M | -$18.3M | |
CATX
Sector
Market Cap
$211.1M
$28.3M
Price % of 52-Week High
52.71%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-4.16%
-1.59%
1-Year Price Total Return
-19.55%
-17.41%
Beta (5-Year)
1.182
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.7925
200-day SMA
Sell
Level
$3.0268
Bollinger Bands (100)
Sell
Level
2.3397 - 3.6797
Chaikin Money Flow
Sell
Level
-69.6M
20-day SMA
Buy
Level
$2.7555
Relative Strength Index (RSI14)
Buy
Level
56.5615
ADX Line
Buy
Level
20.7878
Williams %R
Neutral
Level
-38.0952
50-day SMA
Buy
Level
$2.4850
MACD (12, 26)
Buy
Level
0.0769
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
78.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4535)
Sell
CA Score
(Annual)
Level (-0.4007)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.1808)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
Stock Forecast FAQ
In the current month, CATX has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $12.3077.
-
Where Will Perspective Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Perspective Therapeutics, Inc. share price will rise to $12.3077 per share over the next 12 months.
-
What Do Analysts Say About Perspective Therapeutics, Inc.?
Analysts are divided on their view about Perspective Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.0000.
-
What Is Perspective Therapeutics, Inc.'s Price Target?
The price target for Perspective Therapeutics, Inc. over the next 1-year time period is forecast to be $12.3077 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CATX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Perspective Therapeutics, Inc. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CATX?
You can purchase shares of Perspective Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics, Inc. shares.
-
What Is The Perspective Therapeutics, Inc. Share Price Today?
Perspective Therapeutics, Inc. was last trading at $2.8600 per share. This represents the most recent stock quote for Perspective Therapeutics, Inc.. Yesterday, Perspective Therapeutics, Inc. closed at $2.8400 per share.
-
How To Buy Perspective Therapeutics, Inc. Stock Online?
In order to purchase Perspective Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CATX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CATX
Sector
P/E ratio
--
24.24x
PEG ratio
-0.04x
-0.01x
P/B ratio
0.87x
1.84x
Price / LTM sales
192.56x
1.60x
Growth Metrics
CATX
Sector
Revenue growth
-43.36%
4.6%
Earnings growth
-63.24%
10.71%
Revenue (5-year growth)
-27.61%
6.45%
Earnings forecast
-$0.35
-$0.19
Profitability
CATX
Sector
Profitability FY 2024
-$852K
$3.5M
Return on invested capital
-37.13%
-32.04%
Return on assets
-31.7%
-28.44%
Return on equity
-37.63%
-38.09%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
9
Balance Sheet
CATX
Sector
Total cash
$174.1M
$26.1M
Short term investments
$165.3M
$25.7M
Total assets
$350.1M
$76.4M
Long term debt
$2.6M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
